$50M Clinical Trials Monopoly Auction
Control the language • Build the trust anchor • Define the market
We don’t sell domains — we solve problems.
The first NationalAIComplianceRegistry proved the model: Identify the gap → secure the language → build the neutral trust anchor the market adopts.
Why This Auction Matters
- $68B/year spent globally on trial recruitment flows through digital gateways.
- $20B/year invested in pharma digital compliance & communication.
- Neutral, exact-match domains earn more trust than company-branded portals.
- Owning the language → durable moat in clinical trials & compliance.
The 10 Flagship Domains
ClinicalTrialsRegistry.com / .org
Problem: No neutral global hub for trials.
Audience: Regulators, sponsors, patients.
Solution: The trust anchor for trial transparency.
NationalClinicalTrialsRegistry.com / .org
Problem: Fragmented country-level oversight.
Audience: FDA, EMA, ministries of health.
Solution: Authoritative national trial hub.
GlobalClinicalTrialsRegistry.com / .org
Problem: No universally trusted global registry.
Audience: WHO, NGOs, regulators.
Solution: Unified international platform.
PharmaSponsoredTrials.com / .org
Problem: Public distrust of pharma-funded research.
Audience: Pharma, CROs, NGOs.
Solution: Neutral disclosure hub.
SponsoredTrials.com / .org
Problem: Opaque sponsorship signals.
Audience: Regulators, investors, patient groups.
Solution: Central transparency portal.
ClinicalTrialSponsors.com / .org
Problem: Hard to verify sponsorship at a glance.
Audience: Pharma sponsors, CROs, media.
Solution: Registry of verified trial sponsors.
ClinicalResearchOrganizationsRegistry.com
Problem: Inconsistent CRO credibility.
Audience: Pharma, CROs, investors.
Solution: Oversight hub for CRO quality.
GlobalPharmaRegistry.com / .org
Problem: No unified global pharma identity layer.
Audience: Regulators, investors.
Solution: Registry-level global accountability.
PharmaStocks.com / .org
Problem: Investors lack trial-to-stock clarity.
Audience: Hedge funds, analysts, IR teams.
Solution: Investor hub tied to trial outcomes.
GlobalPharmaTrials.com / .org
Problem: Trial data siloed by geography/company.
Audience: Pharma, CROs, NGOs.
Solution: International visibility layer.